Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP868141.RAp5NVwSvdFzFkYVzN2ZL1nT9PuXBkfKNQErMXQoaROKA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP868141.RAp5NVwSvdFzFkYVzN2ZL1nT9PuXBkfKNQErMXQoaROKA130_assertion type Assertion NP868141.RAp5NVwSvdFzFkYVzN2ZL1nT9PuXBkfKNQErMXQoaROKA130_head.
- NP868141.RAp5NVwSvdFzFkYVzN2ZL1nT9PuXBkfKNQErMXQoaROKA130_assertion description "[Our study suggests that both HDACi/EGFR inhibitor-combination treatment and lapatinib-single treatment may be effective options for the therapy of NSCLC with KRAS mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP868141.RAp5NVwSvdFzFkYVzN2ZL1nT9PuXBkfKNQErMXQoaROKA130_provenance.
- NP868141.RAp5NVwSvdFzFkYVzN2ZL1nT9PuXBkfKNQErMXQoaROKA130_assertion evidence source_evidence_literature NP868141.RAp5NVwSvdFzFkYVzN2ZL1nT9PuXBkfKNQErMXQoaROKA130_provenance.
- NP868141.RAp5NVwSvdFzFkYVzN2ZL1nT9PuXBkfKNQErMXQoaROKA130_assertion SIO_000772 21271222 NP868141.RAp5NVwSvdFzFkYVzN2ZL1nT9PuXBkfKNQErMXQoaROKA130_provenance.
- NP868141.RAp5NVwSvdFzFkYVzN2ZL1nT9PuXBkfKNQErMXQoaROKA130_assertion wasDerivedFrom befree-2016 NP868141.RAp5NVwSvdFzFkYVzN2ZL1nT9PuXBkfKNQErMXQoaROKA130_provenance.
- NP868141.RAp5NVwSvdFzFkYVzN2ZL1nT9PuXBkfKNQErMXQoaROKA130_assertion wasGeneratedBy ECO_0000203 NP868141.RAp5NVwSvdFzFkYVzN2ZL1nT9PuXBkfKNQErMXQoaROKA130_provenance.